With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
In the latest trading session, Amgen (AMGN) closed at $234.72, marking a +1.74% move from the previous day.
Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker have been included in this Analyst Blog.